• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

pT NM期食管鳞状细胞癌患者行R0食管切除术及两野淋巴结清扫术治疗后的生存风险预测模型

Survival risk prediction model for patients with pT NM esophageal squamous cell carcinoma after R0 esophagectomy with two-field lymphadenectomy for therapeutic purposes.

作者信息

Qi Zhan, Hu Yuanping, Qiu Rong, Li Juan, Li Yuekao, He Ming, Wang Yuxiang

机构信息

Department of thoracic surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.

Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, No.12, Jiankang road, Shijiazhuang, 050011, China.

出版信息

J Cardiothorac Surg. 2021 May 1;16(1):121. doi: 10.1186/s13019-021-01503-0.

DOI:10.1186/s13019-021-01503-0
PMID:33933129
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8088719/
Abstract

BACKGROUND

The overall survival (OS) remains unsatisfactory in patients with esophageal squamous cell carcinoma (ESCC) after extended esophagectomy with two-field lymphadenectomy. Therefore, this retrospective study aimed to identify the risk factors that contribute to the low survival of patients with pTNM ESCC.

METHODS

Patients with pTNM ESCC who only underwent R0 esophagectomy with two-field lymphadenectomy in our department from January 2008 to December 2012 were retrospectively enrolled in this study and medical records were reviewed. Postoperative OS, disease-free survival (DFS), recurrence-free survival (RFS), and locoregional recurrence-free survival (LRFS) were analyzed sequentially.

RESULTS

This study recruited a total of 488 patients, whose follow-up visits were completed at the end of December 2019. The five-year OS, DFS, RFS and LRFS rates were 62.1, 53.1, 58.3 and 65.6%, respectively. Multivariate Cox analysis identified patient age, site of the lesion, small mediastinal lymph nodes in CT imaging (SLNs in CT), dissected lymph nodes (LNs), and stage of esophageal malignancy as independent risk factors for OS of the patients. Of these factors, the site of the lesion, SLNs in CT and stage of the cancer were determined to be independent factors for DFS, RFS and LRFS. Based on all five factors, the recursive partitioning analysis (RPA) score system was developed to stratify the patients into low-, medium- and high-risk groups, which were found to possess significantly different rates of OS, DFS, RFS and LRFS (p < 0.001).

CONCLUSIONS

Several factors were associated with the survival of patients with pT NM ESCC who underwent extended esophagectomy with two-field lymphadenectomy. These factors contributed to the RPA scoring system, which could stratify the risk of postoperative survival and may expedite the initiation of postoperative adjuvant therapy.

摘要

背景

在接受扩大食管切除术加两野淋巴结清扫术的食管鳞状细胞癌(ESCC)患者中,总生存期(OS)仍不尽人意。因此,本回顾性研究旨在确定导致pTNM期ESCC患者生存率低的危险因素。

方法

回顾性纳入2008年1月至2012年12月期间在我科仅接受R0食管切除术加两野淋巴结清扫术的pTNM期ESCC患者,并查阅病历。依次分析术后总生存期(OS)、无病生存期(DFS)、无复发生存期(RFS)和区域无复发生存期(LRFS)。

结果

本研究共纳入488例患者,其随访于2019年12月底完成。五年OS、DFS、RFS和LRFS率分别为62.1%、53.1%、58.3%和65.6%。多因素Cox分析确定患者年龄、病变部位、CT影像中的小纵隔淋巴结(CT中的SLN)、清扫淋巴结(LN)和食管恶性肿瘤分期为患者OS的独立危险因素。在这些因素中,病变部位、CT中的SLN和癌症分期被确定为DFS、RFS和LRFS的独立因素。基于所有五个因素,开发了递归划分分析(RPA)评分系统,将患者分为低、中、高风险组,发现这些组的OS、DFS、RFS和LRFS率有显著差异(p<0.001)。

结论

几个因素与接受扩大食管切除术加两野淋巴结清扫术的pTNM期ESCC患者的生存相关。这些因素促成了RPA评分系统,该系统可以对术后生存风险进行分层,并可能加快术后辅助治疗的启动。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f17/8088719/c89164f49483/13019_2021_1503_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f17/8088719/205fea23c3d0/13019_2021_1503_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f17/8088719/c89164f49483/13019_2021_1503_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f17/8088719/205fea23c3d0/13019_2021_1503_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f17/8088719/c89164f49483/13019_2021_1503_Fig2_HTML.jpg

相似文献

1
Survival risk prediction model for patients with pT NM esophageal squamous cell carcinoma after R0 esophagectomy with two-field lymphadenectomy for therapeutic purposes.pT NM期食管鳞状细胞癌患者行R0食管切除术及两野淋巴结清扫术治疗后的生存风险预测模型
J Cardiothorac Surg. 2021 May 1;16(1):121. doi: 10.1186/s13019-021-01503-0.
2
The impact of lymphadenectomy on lymph node recurrence after performing various treatments for esophageal squamous cell carcinoma.各种食管癌治疗方法后淋巴结复发的淋巴结清扫影响。
BMC Surg. 2022 May 11;22(1):171. doi: 10.1186/s12893-022-01618-8.
3
[Patterns of recurrence in patients with stage pT3N0M0 thoracic esophageal squamous cell carcinoma after two-field esophagectomy].[两野淋巴结清扫食管切除术治疗胸段pT3N0M0期食管鳞状细胞癌患者的复发模式]
Zhonghua Zhong Liu Za Zhi. 2016 Jan;38(1):48-54. doi: 10.3760/cma.j.issn.0253-3766.2016.01.010.
4
Extended Right Thoracic Approach Compared With Limited Left Thoracic Approach for Patients With Middle and Lower Esophageal Squamous Cell Carcinoma: Three-year Survival of a Prospective, Randomized, Open-label Trial.经右胸入路与经左胸入路治疗中下段食管鳞癌的前瞻性随机开放标签临床试验:3 年生存分析。
Ann Surg. 2018 May;267(5):826-832. doi: 10.1097/SLA.0000000000002280.
5
[Factors affecting on long-time survival in patients with stage Ⅲ thoracic esophageal carcinoma after esophagectomy].[影响Ⅲ期胸段食管癌患者食管癌切除术后长期生存的因素]
Zhonghua Zhong Liu Za Zhi. 2016 Jul;38(7):530-7. doi: 10.3760/cma.j.issn.0253-3766.2016.07.010.
6
Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma.174例R0切除的食管癌和食管胃交界癌的三野淋巴结清扫术:对分期、无病生存期及预后的影响:呼吁对上段食管癌的TNM分类进行调整
Ann Surg. 2004 Dec;240(6):962-72; discussion 972-4. doi: 10.1097/01.sla.0000145925.70409.d7.
7
[Associated factors of postoperative relapse and metastasis in pT1bN0M0-pT4aN0M0 thoracic esophageal squamous cell carcinoma].[pT1bN0M0 - pT4aN0M0期胸段食管鳞状细胞癌术后复发和转移的相关因素]
Zhonghua Wei Chang Wai Ke Za Zhi. 2017 Sep 25;20(9):1045-1049.
8
Survival impact of the number of lymph nodes dissection in patients receiving neoadjuvant chemotherapy for esophageal squamous cell carcinoma.新辅助化疗治疗食管鳞癌患者淋巴结清扫数目对生存的影响。
Dis Esophagus. 2023 Apr 29;36(5). doi: 10.1093/dote/doac082.
9
Impact of thoracic recurrent laryngeal node dissection: 508 patients with tri-incisional esophagectomy.三切口食管癌根治术中胸内喉返神经淋巴结清扫的影响:508 例患者分析。
J Gastrointest Surg. 2014 Jan;18(1):187-93. doi: 10.1007/s11605-013-2411-2. Epub 2013 Nov 16.
10
Cervical lymph node metastasis classified as regional nodal staging in thoracic esophageal squamous cell carcinoma after radical esophagectomy and three-field lymph node dissection.在根治性食管切除术和三野淋巴结清扫术后,颈淋巴结转移在胸段食管鳞状细胞癌中被归类为区域淋巴结分期。
BMC Surg. 2014 Dec 19;14:110. doi: 10.1186/1471-2482-14-110.

引用本文的文献

1
Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy.卡瑞利珠单抗联合新辅助化疗治疗 ESCC 的疗效和安全性及其对食管癌切除术的影响。
Front Immunol. 2022 Jul 14;13:953229. doi: 10.3389/fimmu.2022.953229. eCollection 2022.
2
A Nomogram Model to Predict Post-Progression Survival in Esophageal Squamous Cell Carcinoma Patients With Recurrence After Radical Resection.一种预测根治性切除术后复发的食管鳞状细胞癌患者进展后生存期的列线图模型。
Front Oncol. 2022 Jul 7;12:925685. doi: 10.3389/fonc.2022.925685. eCollection 2022.

本文引用的文献

1
Postoperative Radiotherapy in Pathological T2-3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study.T2-3N0M0 期胸段食管鳞癌术后放疗:一项前瞻性 III 期随机对照研究的中期报告。
Oncologist. 2020 Apr;25(4):e701-e708. doi: 10.1634/theoncologist.2019-0276. Epub 2020 Feb 21.
2
Adjuvant radiotherapy for patients with pathologic node-negative esophageal carcinoma: A population based propensity matching analysis.辅助放疗用于病理淋巴结阴性食管癌患者:基于人群的倾向匹配分析。
Thorac Cancer. 2020 Feb;11(2):243-252. doi: 10.1111/1759-7714.13235. Epub 2019 Dec 11.
3
Comparison of Ivor Lewis esophagectomy and Sweet esophagectomy for the treatment of middle-lower esophageal squamous cell carcinoma.
Ivor Lewis食管癌切除术与Sweet食管癌切除术治疗中下段食管鳞状细胞癌的比较。
J Thorac Dis. 2019 Aug;11(8):3584-3592. doi: 10.21037/jtd.2019.07.68.
4
Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy.列线图预测根治性食管切除术后胸段食管鳞癌患者的总生存。
Ann Surg Oncol. 2019 Sep;26(9):2890-2898. doi: 10.1245/s10434-019-07393-w. Epub 2019 Jun 10.
5
Adjuvant radiotherapy for stage pN1M0 esophageal squamous cell carcinoma: Results from a Chinese two-center study.辅助放疗治疗 pN1M0 期食管鳞癌:来自中国两个中心的研究结果。
Thorac Cancer. 2019 Jun;10(6):1431-1440. doi: 10.1111/1759-7714.13088. Epub 2019 May 17.
6
Comparison of Ivor-Lewis versus Sweet procedure for middle and lower thoracic esophageal squamous cell carcinoma: A STROBE compliant study.Ivor-Lewis术式与Sweet术式治疗胸段中下段食管鳞状细胞癌的比较:一项遵循STROBE规范的研究
Medicine (Baltimore). 2019 Feb;98(6):e14416. doi: 10.1097/MD.0000000000014416.
7
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
8
Three-field versus two-field lymph node dissection for thoracic esophageal squamous cell carcinoma: a propensity score-matched comparison.胸段食管鳞状细胞癌三野与二野淋巴结清扫术的倾向评分匹配比较
J Thorac Dis. 2018 May;10(5):2924-2932. doi: 10.21037/jtd.2018.05.69.
9
Long-term survival of the middle and lower thoracic esophageal cancer patients after surgical treatment through left or right thoracic approach.经左胸或右胸入路手术治疗的胸段中下段食管癌患者的长期生存情况。
J Thorac Dis. 2018 May;10(5):2648-2655. doi: 10.21037/jtd.2018.04.45.
10
Prognostic value of the number of negative lymph nodes in esophageal carcinoma without lymphatic metastasis.食管癌无淋巴转移时阴性淋巴结数的预后价值。
Thorac Cancer. 2018 Sep;9(9):1129-1135. doi: 10.1111/1759-7714.12796. Epub 2018 Jun 28.